NOT FOR HUMAN CONSUMPTION

Melanotan I is a synthetic analog of α-melanocyte-stimulating hormone (α-MSH) that selectively activates the melanocortin-1 receptor (MC1R), stimulating melanogenesis in the skin. Increased eumelanin production enhances pigmentation and can improve natural photoprotection against ultraviolet (UV) radiation. The pharmaceutical form of afamelanotide is approved in several countries for the treatment of erythropoietic protoporphyria (EPP), while Melanotan I sold as a research peptide is not approved for cosmetic tanning and should not be considered equivalent to pharmaceutical-grade afamelanotide.

Additional Benefits of Melanotan I Under Investigation

BenefitKey take-aways1 Increased skin pigmentationProduces gradual, dose-dependent increases in eumelanin, resulting in darker skin pigmentation independent of UV exposure, although limited UV exposure enhances the effect.2 Improved photoprotectionIncreased eumelanin reduces UV-induced DNA damage and sunburn susceptibility, particularly in fair-skinned individuals.3 Erythropoietic protoporphyria (EPP)Pharmaceutical afamelanotide significantly increases pain-free sun exposure and quality of life in patients with EPP.4 Reduced UV-induced oxidative stressExperimental studies demonstrate lower oxidative stress markers following UV exposure due to increased melanin production.5 Potential skin cancer preventionBy reducing cumulative UV damage, Melanotan I may theoretically lower skin cancer risk, although definitive long-term human outcome studies are lacking.6 Improved pigment disordersInvestigational use in vitiligo and other hypopigmentation disorders has shown variable success when combined with phototherapy.7 Cosmetic tanning without excessive UVProduces a darker complexion while reducing the need for prolonged sun exposure compared with conventional tanning.8 Enhanced DNA repair signalingLaboratory models suggest activation of melanocortin pathways may enhance DNA repair following UV damage, although clinical significance remains uncertain.9 Quality of life in photosensitive disordersPatients with severe photosensitivity often report meaningful improvements in outdoor activity and psychological well-being after treatment.

2. Molecular Mechanism of Action

2.1 Receptor Pharmacodynamics

MC1R activation

• Stimulates adenylate cyclase

• Increases intracellular cAMP

• Activates protein kinase A (PKA)

• Upregulates MITF transcription factor

• Increases tyrosinase activity

• Promotes eumelanin synthesis

Unlike Melanotan II, Melanotan I exhibits high selectivity for MC1R and has minimal activity at melanocortin receptors associated with appetite or sexual function.

2.2 Downstream Biology

PathwayFunctional outcomeContextMC1R → cAMPIncreased melanogenesisSkin melanocytesMITF activationIncreased tyrosinase expressionPigment synthesisEumelanin productionDarker pigmentationEpidermisUV absorptionReduced DNA damageSkin protectionAnti-inflammatory signalingReduced UV-induced inflammationExperimental models

3. Pharmacokinetics

Route

• Subcutaneous injection (research peptide)

• Subcutaneous biodegradable implant (approved afamelanotide)

Half-life

• Native peptide is rapidly degraded.

• Melanotan I modifications increase stability compared with endogenous α-MSH but still require repeated administration.

• The approved implant provides sustained release over approximately two months.

Distribution

• Primarily extracellular peptide distribution.

• Acts on melanocytes expressing MC1 receptors.

Metabolism

• Proteolytic degradation into inactive peptide fragments.

Food interactions

• None known.

4. Pre-clinical and Clinical Evidence

4.1 Erythropoietic Protoporphyria

Multiple randomized clinical trials demonstrated:

• significantly longer pain-free sun exposure

• reduced phototoxic reactions

• improved quality of life

• favorable long-term safety under specialist supervision

These findings supported regulatory approval of pharmaceutical afamelanotide for EPP.

4.2 Pigmentation

Clinical studies consistently demonstrate:

• increased eumelanin production

• progressive skin darkening

• reduced UV sensitivity

• greater tanning response with lower UV exposure

Pigmentation develops gradually over several weeks.

4.3 Vitiligo

Early studies combining afamelanotide with narrow-band UVB therapy demonstrated:

• accelerated repigmentation

• improved response compared with UVB alone

• greatest benefit in darker skin phototypes

Larger confirmatory studies remain limited.

Evidence quality note

The strongest evidence supports use in EPP through pharmaceutical afamelanotide. Cosmetic tanning applications rely on smaller studies and off-label experience. Research peptide preparations have not undergone the quality control, safety evaluation, or regulatory review required for approved medicines.

5. Emerging Clinical Interests

FieldRationaleStatusEPPApproved indicationEstablishedVitiligoPigment restorationInvestigationalPolymorphic light eruptionImproved UV toleranceEarly studiesSolar urticariaPhotosensitivity reductionExploratoryPrevention of UV damageIncreased eumelaninExperimentalGenetic photosensitivity disordersPhotoprotectionInvestigational

6. Safety and Tolerability

Common (generally mild)

• nausea

• facial flushing

• fatigue

• headache

• injection-site discomfort

• transient appetite reduction

Skin

• generalized skin darkening

• darkening of freckles

• darkening of existing moles

Regular dermatologic skin examinations are recommended for patients receiving long-term therapy because pigmented lesions become more noticeable.

Cardiovascular

• generally minimal cardiovascular effects

• occasional mild blood pressure changes

Gastrointestinal

• mild nausea is the most common adverse effect

• significantly less gastrointestinal intolerance than GLP-1 receptor agonists

Cancer

Current evidence has not demonstrated that pharmaceutical afamelanotide causes melanoma or other skin cancers. However, any new, changing, or atypical pigmented lesion should be evaluated by a dermatologist. Long-term surveillance continues.

Contraindications / caution

• pregnancy and breastfeeding

• hypersensitivity to the product

• use only under specialist supervision for approved indications

Comparative Safety Matrix

FeatureMelanotan IMelanotan IIPrimary receptorMC1R selectiveMC1R + broader melanocortin activityPigmentationHighHighAppetite suppressionMinimalMildSexual effectsMinimalCommonNauseaMildModerateFlushingMildModeratePriapism riskVery rareIncreasedClinical approvalPharmaceutical afamelanotide for EPPNone

7. Regulatory Landscape

Approved pharmaceutical

Afamelanotide implant is approved in multiple regions for the treatment of erythropoietic protoporphyria under specialist care.

Research peptide

Melanotan I sold online as a "research chemical" has no approval for cosmetic tanning. Manufacturing quality, purity, sterility, and dosage may vary substantially between suppliers.

8. Future Directions

• Expanded use in vitiligo

• Additional photosensitivity disorders

• Improved sustained-release formulations

• Long-term skin cancer prevention studies

• Personalized treatment according to MC1R genotype

• Combination therapies with phototherapy and dermatologic treatments

Selected References

• New England Journal of Medicine, Clinical trials of afamelanotide in erythropoietic protoporphyria.

• The Lancet, Afamelanotide and photoprotection in photosensitivity disorders.

• Journal of Investigative Dermatology, MC1R signaling and melanogenesis.

• Pigment Cell & Melanoma Research, Melanocortin biology and pigment disorders.

• British Journal of Dermatology, Afamelanotide in vitiligo and photoprotection.

• Photodermatology, Photoimmunology & Photomedicine, Clinical applications of melanocortin analogues.

Evidence quality note: Most high-quality clinical evidence relates to pharmaceutical afamelanotide for EPP. Claims regarding cosmetic tanning, skin cancer prevention, and other investigational uses remain less well established and require additional long-term randomized studies.